TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04891926

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ICIQ FLUTS Questionaires
Description: Questionnaire observing the impact on voiding disfunctions

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Frequency Volume Chart
Description: Frequency Volume Chart measures the voided volumes and fluid intake during 3 days in order to observe patients bladder capacity, total and nighttime voided volume and voiding frequency

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Renal Function Profile
Description: The RFP is a 24-hour urine analysis in which urine samples are collected at fixed time points every 3 hours, starting 3 hours after the first morning void. This RFP was collected on a separated day to the FVC. Daytime samples were taken between 10:00-11:30 (U1), 13:00-15:30 (U2), 16:00-17:30 (U3), 19:00-20:30 (U4), and 22:00-23:30 (U5). The night-time samples were taken between 1:00-2:30 (U6), 4:00-5:30 (U7) and 7:00-8:30 (U8), and the volume of each interim void, was noted to calculate the 24h, daytime and night-time urine volume and diuresis rate. On each of this 8 samples, creatinine, osmolality, sodium and urea concentration were analysed. Subsequently, the renal clearance of creatinine, solutes, sodium and potassium (Usubst x Uflow / Psubst) and FWC (urine flow - solute clearance) were calculated.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood Analysis
Description: Blood analysis in order to observ postmenopausal state, osmolalitity and sodium.
Study: NCT01343784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urinary voiding assessment after midurethral sling
Description: Both groups will undergo voiding trial in the similar manner. The decision to discharge based on an objective measure (voided amount) versus based on the subjective measure (force of stream self assessment).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Urinary voiding assessment after midurethral sling
Description: Both groups will undergo voiding trial in the similar manner. The decision to discharge based on an objective measure (voided amount) versus based on the subjective measure (force of stream self assessment).
Study: NCT04350164

Intervention type: DRUG
Intervention: Romiplostim
Description: romiplostim once weekly subcutaneously at an initial dose of 8-9 µg/kg per week for at least 1 month to 1 year.
Study: NCT02496741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and chloroquine combination
Description: Metformin and chloroquine are two oral medications. Metformin is to be taken twice daily, chloroquine once daily.
Study: NCT03992898

Intervention type: OTHER
Intervention: No special intervention was suitable for this observational study
Description: Investegators divided patients into 3 corhort according to the liver condition at enrollment (i.e. chronic liver disease, compemsated cirrhosis, decompensated cirrhosis). All patients received standard medical treatment, including nutritional supplementation; administration of human serum albumin, fresh frozen plasma, antivirus treatment and appropriate treatment for complications. No special intervention was suitable for this observational study.

Intervention type: OTHER
Intervention: No special intervention was suitable for this observational study
Description: Investegators divided patients into 3 corhort according to the liver condition at enrollment (i.e. chronic liver disease, compemsated cirrhosis, decompensated cirrhosis). All patients received standard medical treatment, including nutritional supplementation; administration of human serum albumin, fresh frozen plasma, antivirus treatment and appropriate treatment for complications. No special intervention was suitable for this observational study.
Study: NCT00983138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant asparaginase
Description: 10 000 Units/m² adjusted to age, 6 i.v. infusions (day 15, day 18, day 22, day 25, day 29, day 33) during the induction therapy
Study: NCT00651144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe + Rosuvastatin
Description: oral tablets; rosuvastatin 10 mg + ezetimibe 10 mg, once daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: oral tablets; rosuvastatin 10 mg + ezetimibe placebo once daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablets; two ezetimibe placebo once daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: oral tablets; ezetimibe 10 mg + ezetimibe placebo once daily for 14 days
Study: NCT00544908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study: NCT03294824

Intervention type: OTHER
Intervention: blood sample
Description: peripheral blood samples are collected

Intervention type: OTHER
Intervention: blood sample
Description: peripheral blood samples are collected

Intervention type: OTHER
Intervention: blood sample
Description: peripheral blood samples are collected
Study: NCT01485120

Intervention type: DEVICE
Group type: OTHER
Intervention: BP monitoring using two methods
Description: BP readings from participant using invasive radial arterial line, Non-invasive cuff with SuperSTAT NIBP algorithm, and Non-invasive cuff with Classic NIBP algorithm.
Study: NCT02493946

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01831037

Intervention type: OTHER
Intervention: Regression of fibrosis
Description: Regression of fibrosis will be defined by assessing yearly evolution of noninvasive markers in patients who received antiviral therapy before start of the study, and by comparing baseline markers before start of antiviral therapy to those on subsequent yearly visits in patients prospective recruited (\>50% of cases).

Intervention type: OTHER
Intervention: Specific risk factors related to hepatocellular carcinoma
Description: Such as: family history of liver cancer; body mass index; alcohol, smoking and recreational drug use status; dietary habits, including use of caffeinated drinks; comorbidities such as type 2 diabetes mellitus; use of medications for other chronic diseases such as statins and angiotensin-converting enzyme inhibitors.
Study: NCT02593123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO, by mouth, orally or IV, intravenous medication administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: Given PO, by mouth, orally or IV, intravenous medication administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: GM-CSF beginning post-transplant day 4 and continuing until hematopoietic reconstitution. Patients in the MMF-15 cohort will receive sargramostim (GM-CSF) 250 mcg/m2/day beginning on post-transplant day 4 and continuing until neutrophil engraftment.~Patients receiving GM-CSF will also receive inhaled corticosteroids, fluticasone (Flovent) 2 puffs twice daily, starting on post-transplant day 4 and stopping after cessation of GM-CSF, to diminish the risk of pneumonitis.~Note: At investigator discretion, patients in the MMF-15 cohort who have preexisting pulmonary risk factors, will be permitted to receive G-CSF.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: G-CSF beginning post-transplant day 4 and continuing until hematopoietic reconstitution. Patients in the MMF-30 cohort will receive filgrastim (G-CSF) 5 mcg/kg/day beginning on post-transplant day 4 and continuing until neutrophil engraftment.
Study: NCT03940690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-VEGF injections of bevacizumab
Description: 5 anti-VEGF injections of bevacizumab at months 0, 1, 2, 4 and 6, combined with laser at months 2, 4 and 6 (laser optional at month 9)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: 3 sessions of laser at months 0, 1 and 2, completed if needed with laser at months 4, 6 et and 9
Study: NCT02638883

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid SRW cochlear implant
Description: Subjects will be implanted with the Hybrid SRW
Study: NCT02519946

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: On-Line Diet and Exercise Intervention
Description: Initial 16 weeks of on-line, live exercise instruction 3x/week and on-line, diet sessions followed by 16 weeks of weekly exercise and diet sessions.
Study: NCT00431613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 IV on day 8 every 3 weeks for 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 IV on day 8 every 3 weeks for 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1100 mg/m2 on days 1 and 8 every 3 weeks for 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1100 mg/m2 on days 1 and 8 every 3 weeks for 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin 6AUC IV on day 1 every 3 weeks for 3 cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: After 21 days from the 2nd chemotherapy cycle definitive concurrent chemoradiotherapy will be started: daily fractions of 1.8 Gy for 5 days/week, for a total dose of 45 Gy.~During the radiotherapy docetaxel 25 mg/m2, IV, will be administered on days 1, 8, 15, 22, 29 and carboplatin 2AUC, IV , on days 4, 11, 18, 25, 32

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: After 21 days from the 2nd chemotherapy cycle definitive concurrent chemoradiotherapy will be started: daily fractions of 1.8 Gy for 5 days/week, for a total dose of 45 Gy.~During the radiotherapy docetaxel 25 mg/m2, IV, will be administered on days 1, 8, 15, 22, 29 and carboplatin 2AUC, IV , on days 4, 11, 18, 25, 32

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m2 IV on day 1 for 3 cycles
Study: NCT00356005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin plus artesunate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate
Study: NCT01193010

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Surgical Planning
Description: Using a CT reconstructing of affected distal radius and the normal contralateral limb, surgical guides for the osteotomy will be created to assist with surgical planning.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: distal radius osteotomy
Description: In this control group, the planning and surgical execution of the distal radius osteotomy will be performed as usual, without computer-assisted planning of the osteotomy.
Study: NCT00843427

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CIAT
Description: Patients are to receive constraint-induced aphasia therapy for 2 weeks at 4 hours per day. Detailed description of this intervention is in Szaflarski et al., 2015 Medical Science Monitor.
Study: NCT00905047

Intervention type: DRUG
Group type: OTHER
Intervention: XELODA
Description: XELODA, 2500 mg/m²/bid, with approximatively an interval of 12 hours, 30 minutes after breakfast and dinner - during 14 days.~Cycle treatment duration : 21 days

Intervention type: DRUG
Group type: OTHER
Intervention: TEGAFUR URACIL - FOLINIC ACID
Description: Tegafur 300 mg/m2/tid with folinic acid 75 mg/tid during 28 days.~Duration of treatment cycle : 35 days.
Study: NCT05396508

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interfacial injection
Description: 10 ml of bupivacaine and steroid injection was applied between the leaves of the thoracolumbar fascia under the guidance of ultrasonography.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Description: protocol including hot pack for 20 min/session, therapeutic continuous Ultrasound (frequency, 1 MHz; intensity 1.5 W/cm2) for 6 min/session, therapeutic exercises for low back muscles. Therapeutic exercises included stretching ,posterior pelvic tilt ,hyperextension ,bridge and cat-camel exercises

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Description: protocol including hot pack for 20 min/session, therapeutic continuous Ultrasound (frequency, 1 MHz; intensity 1.5 W/cm2) for 6 min/session, therapeutic exercises for low back muscles. Therapeutic exercises included stretching ,posterior pelvic tilt ,hyperextension ,bridge and cat-camel exercises
Study: NCT00895895

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules SAM-531 placebo and 5 mg tablet encapsulated Donepezil placebo capsules, once a day during 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAM-531 1.5 mg
Description: Capsules SAM-531 1.5 mg, once a day during 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAM-531 3.0 mg
Description: Capsules SAM-531 3.0 mg, once a day during 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAM-531 5.0 mg
Description: Capsules SAM-531 5.0 mg, once a day during 24 weeks or 52 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Encapsulated Donepezil 5 mg tablets, once a day during 52 weeks. After Day 42, the dose can up titrated up to 10 mg of Donepezil.
Study: NCT00560144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: 3mg/kg iv weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: 9mg/kg iv weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: Pharmacokinetic-derived dose, \<=16mg/kg iv weekly
Study: NCT03690427

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional hookah smoking
Description: Charcoal-heated hookah smoking

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional hookah smoking
Description: Charcoal-heated hookah smoking

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic hookah vaping
Description: Electronic hookah bowl inhalation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic hookah vaping
Description: Electronic hookah bowl inhalation
Study: NCT00673907

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Wood smoke particles
Description: Subjects are exposed at rest to the exposures for 3 h in our climate chamber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wood smoke particles
Description: Subjects are exposed at rest to the exposures for 3 h in our climate chamber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wood smoke particles
Description: Subjects are exposed at rest to the exposures for 3 h in our climate chamber
Study: NCT03798873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FeelWell™ Compression garment
Description: Registered FDA class I device:~The FeelWell™ Compression garment is a custom-made orthopedic abdominal binder with full or half-body support. The garments are made of 70% polyamide and 30% elastane and OEKO-TEX certified confirming human-ecological safety of textiles. The company uses a wrap knitting to ensure an optimal compression and durability. The garment has two 360 degrees whalebones in the front and two in the back to provide support for the posture, reinforcing compression on the abdomen and lower-back.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase Mobility
Description: Subjects will work with exercise physiologist and physical therapist to increase mobility, strength and activity

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Increase Mobility
Description: Subjects will work with exercise physiologist and physical therapist to increase mobility, strength and activity
Study: NCT04787237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VST and immediate implants
Description: One-cm long vestibular access incision was made using a 15c blade 3-4 mm apical to the mucogingival junction at the related socket . A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision using periotomes and micro periosteal elevators (. Implant fixture were then inserted after drilling to its pre-planned location 3-4 mm apical to socket base with adequate primary stability achieved using a torque wrench reaching 30 Ncm torque . A flexible cortical membrane shield that is made of cortical bone of heterologous origin of 0.6 mm thickness was hydrated and then trimmed and introduced from the vestibular access incision reaching 1 mm below the socket orifice through the tunnel . The socket gap between the implant and the shield was then packed thoroughly with particulate bone graft

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Buser technique and early implants placement
Description: In Buser's group early implant placement, the failing tooth was extracted atraumatically using a periotome. A collagen plug was placed to stabilize the wound clot. A healing period of 4-8 weeks (depending on the size of the extracted tooth) was followed. Then an open flap implant surgery using a triangular flap design was cut. After preparing the implant bed, the site was irrigated using normal saline. A healing abutment was then attached. Contour augmentation was done using autogenous bone chips mixed with saline and bone. A non-cross liked membrane was then placed, after being soaked with BCM. Finally, the healing abutment was removed and the flap was released to allow for its suturing.
Study: NCT04264715

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 405nm light
Description: In this room, surgeries will be performed under ambient light including the wavelength 405nm
Study: NCT00098527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: romidepsin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02931305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epimedium Prenylflavonoids Extract
Description: Each Epimedium Prenylflavonoids Extract capsule contains 370 mg of EPIMEDIUM EXTRACT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Use iron oxide (brown, black and yellow) to mimic Epimedium Prenylflavonoids Extract.
Study: NCT01465945

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Defect Unsutured
Description: The defect is not sutured after the rectal tumor is removed by TEM.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Defect Sutured
Description: Defect is sutured after the rectal tumor has been removed by TEM.
Study: NCT01224470

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexamedetomidine intravenous injection (1 ㎍/kg )

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexamedetomidine intravenous injection (1 ㎍/kg )
Study: NCT00281320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: Asenapine 2 mg twice daily (BID) on Days 1 and 2, 5 mg BID on Days 3 and 4, followed by 10 mg BID on Day 5 through the end of the trial (Week 6); or Asenapine 5 mg BID on Days 1 to 4 followed by 10 mg BID on Day 5 through the end of the trial (Week 6).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: Asenapine 2 mg twice daily (BID) on Days 1 and 2, 5 mg BID on Days 3 and 4, followed by 10 mg BID on Day 5 through the end of the trial (Week 6); or Asenapine 5 mg BID on Days 1 to 4 followed by 10 mg BID on Day 5 through the end of the trial (Week 6).
Study: NCT00798434

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo administered orally in the morning or evening.
Study: NCT00544908

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study: NCT00974038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychotherapy
Description: 1) cognitive-behavioral therapy or 2) supportive psychotherapy
Study: NCT03603288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idebenone 150 mg film-coated tablets
Description: 900 mg idebenone/day
Study: NCT01592604

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compressive bandage
Description: Compressive below knee bandage for 4 weeks in group A

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Below knee walking cast
Description: Below knee walking cast for 4 weeks
Study: NCT01474161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GFT505 120mg - old formulation
Description: hard gelatin capsules dosed at 60mg, one single oral administration (Study part I), 6 capsules with 250mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFT505 120mg - new formulation
Description: hard gelatin capsules dosed at 60mg, one single oral administration (Study Part I) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 2 capsules with 250mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFT505 180mg - new formulation
Description: hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 3 capsules with 250mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFT505 240mg - new formulation
Description: hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III), 4 capsules with 250mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFT505 300mg - new formulation
Description: hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II), 5 capsules with 250mL of water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: hard gelatin capsules, one single oral administration (3 to 5 capsules with 250mL of water for Study Part II) or multiple dose administration from Day 1 to Day 14 (2 to 4 capsules with 250mL of water for Study Part III).
Study: NCT03899402

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Standard of care insulin for pump or injection and serves as a control
Study: NCT00798434

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fesoterodine fumarate
Description: Fesoterodine fumarate is an antimuscarinic drug recently approved by the European Medicines Evaluation Agency for treatment of symptoms of overactive bladder syndrome.